Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Claritas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107
Details : R-107 is a liquid, nitric oxide-releasing compound with issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia and South Korea.
Product Name : R-107
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 21, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Claritas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement